This is an old revision of this page, as edited by Beetstra (talk | contribs) at 20:39, 10 November 2011 (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'DrugBank').). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 20:39, 10 November 2011 by Beetstra (talk | contribs) (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'DrugBank').)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Clinical data | |
|---|---|
| Trade names | Omnicef |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a698001 |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 16% to 21% (dose-dependent) |
| Protein binding | 60% to 70% |
| Metabolism | Negligible |
| Elimination half-life | 1.7 ± 0.6 hours |
| Excretion | Renal |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.171.145  |
| Chemical and physical data | |
| Formula | C14H13N5O5S2 |
| Molar mass | 395.416 g/mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Cefdinir (marketed by Abbott Laboratories under the brand name Omnicef) is a semi-synthetic, broad-spectrum antibiotic in the third generation of the cephalosporin class, proven effective for common bacterial infections of the ear, sinus, throat, and skin. It was approved by the U.S. Food and Drug Administration (FDA) in December 1997.
As of 2008, cefdinir was the highest-selling cephalosporin antibiotic in the United States, with more than US$585 million in retail sales of its generic versions alone.
Mechanism of action
Main article: CephalosporinIndications
Therapeutic uses of cefdinir include otitis media, soft tissue infections, and respiratory tract infections, including sinusitis, strep throat, community-acquired pneumonia and acute exacerbations of bronchitis.
Susceptible organisms
Cefdinir is a bacteriocidal antibiotic. It can be used to treat infections caused by several Gram-negative and Gram-positive bacteria.
Side effects
According to the Omnicef website, side effects include "(...) diarrhea, vaginal infections or inflammation, nausea, headache, and abdominal pain."
Available forms
Cefdinir is administered orally. It is available as capsules and a suspension. Dosage, schedule, and duration of therapy varies according to the type of infection.
Cefdinir is available as a generic drug.
"Blood" in the Stool
The pediatric version of Omnicef can bind to iron in the digestive tract. In rare cases, this creates a discoloration of the stool to a rust or red color. Some patients may interpret this as blood in the stool, although in reality blood appears dark brown or black in the stool. A doctor's office can perform a simple test on the stool to confirm that it does not have blood. If you simply wait one hour, the red color will remain red, (while real blood will turn black).
On the other hand, if the reddish stool is accompanied by abdominal pain, weight loss, diarrhea, etc., it could be a C. difficile (clostridium difficile) infection caused by the antibiotic. This infection can occur as a result of taking an antibiotic. Talk to your pediatrician immediately to see if you should stop using the antibiotic.
References
- Template:PDFlink. Drug Topics (May 26, 2009). Retrieved on July 24, 2009.
- "Omnicef capsules Patient Information" (PDF). Abbott Laboratories. 2004. Archived from the original (PDF) on 2006-11-18. Retrieved 2006-11-24.
{{cite web}}: Unknown parameter|month=ignored (help)
U.S. Prescribing Information from Omnicef.com